IDEAYA Biosciences

161 articles about IDEAYA Biosciences

• IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations

  9/26/2023

  IDEAYA Biosciences, Inc. announces that the U.S. FDA has granted Fast Track designation to IDEAYA's development program investigating IDE161, a potent and selective inhibitor of poly glycohydrolase, for the treatment of adult patients having advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations who are platinum resistant and have received prior antiangiogenic and poly polymerase inhibitor therapies.

• IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors

  9/11/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announces initiation of a Phase 1 monotherapy expansion in the first-in-human clinical trial evaluating IDE161.

• IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events

  9/5/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.

• IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

  8/21/2023

  IDEAYA Biosciences, Inc. announced the clearance of an Investigational New Drug application with the U.S. FDA for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101, a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of poly- polymerase, for the treatment of patients having tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency.

• IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma

  8/16/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma patients.

• IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/10/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2023.

• IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors

  8/2/2023

  IDEAYA Biosciences, Inc. announced achievement of First-Patient-In for the Amgen-sponsored Phase 1/2 clinical trial evaluating the combination of IDE397, the IDEAYA investigational MAT2A inhibitor, and AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having tumors with MTAP deletion, with an expansion focus in NSCLC.

• IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event

  8/1/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 28, 2023

  7/28/2023

  IDEAYA Biosciences, Inc. announced that, on July 27, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company's common stock to two newly hired employees.

• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 30, 2023

  6/30/2023

  IDEAYA Biosciences, Inc. announced that, on June 29, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 162,400 shares of the Company's common stock to five newly hired employees.

• IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy

  6/22/2023

  IDEAYA Biosciences, Inc. announced a first reported case of a uveal melanoma patient who was treated with single agent darovasertib as neoadjuvant therapy and was spared enucleation in an Investigator Sponsored Trial.

• IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

  6/12/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a monotherapy expansion dose for the Phase 2 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion.

• IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events

  5/30/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.

• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 26, 2023

  5/26/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that, on May 25, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a newly hired employee.

• IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

  5/22/2023

  IDEAYA Biosciences, Inc. announced that the U.S. Food and Drug Administration has completed its review of the Amgen-sponsored Investigational New Drug application and concluded that the proposed clinical study may proceed to evaluate IDE397 in combination with AMG 193 in solid tumors having MTAP deletion.

• IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

  5/16/2023

  IDEAYA Biosciences, Inc. announced that it has amended its clinical trial collaboration and supply agreements with Pfizer Inc. to support evaluation of darovasertib and crizotinib combination therapy in the company's planned Phase 2/3 registrational clinical trial in MUM and to continue support of the company's ongoing Phase 2 clinical trial in MUM.

• IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

  5/9/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter ended March 31, 2023.

• IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event

  5/1/2023

  IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event.

• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 28, 2023

  4/28/2023

  IDEAYA Biosciences, Inc. announced that, on April 27, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a newly hired employee.

• IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - April 27, 2023

  4/27/2023

  IDEAYA Biosciences, Inc. announced the closing of its underwritten public offering of 8,858,121 shares of its common stock at a public offering price of $18.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 2,020,270 shares of common stock at a public offering price of $18.4999 per pre-funded warrant, before underwriting discounts and commissions.